New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:47 EDTCARACara Therapeutics price target raised to $29 from $25 at Canaccord
Canaccord raised its price target on Cara Therapeutics to $29 from $25 on the CRS-45's potential in adjunct post-operative pain relief. The firm expects positive Phase 3 data in the second half of 2015 and could have potential US sales of $750M. Shares are Buy rated.
News For CARA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
19:11 EDTCARACara Therapeutics 3.76M share Secondary priced at $18.60
Subscribe for More Information
July 27, 2015
19:03 EDTCARAOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTCARACara Therapeutics files to sell $65M in common stock
Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering. Canaccord Genuity Inc., Needham & Company, LLC and Janney Montgomery Scott LLC are acting as co-managers.
July 23, 2015
09:13 EDTCARAOn The Fly: Pre-market Movers
Subscribe for More Information
07:28 EDTCARACara announces 'significant' toline results from Phase 2 CR845 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use